CWC22

Across TCGA pan-cancer cohorts, CWC22 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated CWC22 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher CWC22 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CWC22 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

LUSC, SCLC, and LIHC are the cancer types where CWC22 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	II,III,IV	0.214	0.750	<.001	36	view →
SCLC	DFS	Median	All	0.164	0.625	.018	12	view →
LIHC	OS	Median	All	0.098	0.774	.002	9	view →
UCEC	DFS	Median	II,III,IV	0.928	0.435	.020	8	view →
SARC	DFS	Median	All	0.006	0.611	<.001	6	view →
BLCA	DFS	Median	All	1.000	0.329	.041	4	view →
ESCA	OS	Median	II,III,IV	0.277	0.686	.026	3	view →
GBM	DFS	Median	All	1.000	0.192	.036	2	view →
LUAD	OS	Median	II,III,IV	0.554	0.709	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

CWC22–LUSC (OS)

Open the LUSC breakdown →